The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a significant substantial loss in body mass and benefit metabolic marker